Kyverna Therapeutics (KYTX) Assets Average (2024 - 2026)
Kyverna Therapeutics' (KYTX) quarterly Assets Average came in at $275.4 million in Q1 2026, down 2.56% YoY from $282.6 million in Q1 2025, and up 14.53% on a QoQ basis from $240.5 million in Q4 2025.
Kyverna Therapeutics (KYTX) Assets Average (2024 - 2026) Analysis & Trends
Kyverna Therapeutics (KYTX) has 3 years of Assets Average data on file, last reported at $275.4 million in Q1 2026.
- Quarterly Assets Average fell 2.56% year-over-year to $275.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $275.4 million (down 2.56% YoY) and the FY2025 annual result came in at $299.2 million, up 57.56% from the prior year.
- Assets Average grew to $275.4 million in Q1 2026, from $240.5 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $376.6 million in Q2 2024 to a low of $206.8 million in Q3 2025.
- A 3-year average of $281.2 million and a median of $275.4 million in 2026 frame the typical range for Assets Average.
- The widest YoY moves for Assets Average: up 21.52% in 2025, down 41.1% in 2025.
- Tracing KYTX's Assets Average over 3 years: stood at $321.9 million in 2024, then dropped by 25.29% to $240.5 million in 2025, then advanced by 14.53% to $275.4 million in 2026.
- The last three Assets Average figures came in at $275.4 million (Q1 2026), $240.5 million (Q4 2025), and $206.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Kyverna Therapeutics | 505.26 Mn | 505.26 Mn | - | 238.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 238.42 Mn |
| Mar 31, 2026 | 275.43 Mn |
| Dec 31, 2025 | 240.49 Mn |
| Sep 30, 2025 | 206.83 Mn |
| Jun 30, 2025 | 243.58 Mn |
| Mar 31, 2025 | 282.65 Mn |
| Dec 31, 2024 | 321.92 Mn |
| Sep 30, 2024 | 351.16 Mn |
| Jun 30, 2024 | 376.55 Mn |
| Mar 31, 2024 | 232.59 Mn |